Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy
Luca Fazzini(Mayo Clinic), Christian Cadeddu Dessalvi(University of Cagliari), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), N Campana(University of Cagliari), Concetta Zito(University of Messina), Cristina Madaudo(University of Palermo), Daniela Di Lisi, Nicola Maurea(Cancer Institute (WIA)), Stefano Cossu(University of Cagliari), Martino Deidda(University of Cagliari), Giuseppina Novo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo)
Cited by 8
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study
|European Heart Journal - Cardiovascular Imaging|2018|336
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
|Frontiers in Physiology|2018|154
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
|Antioxidants and Redox Signaling|2017|122
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116